NEW YORK, May 11, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the first quarter 2023 and provided a corporate and commercial update.
"During the first quarter, we continued to improve the financial profile of the Company as we capitalized on the growing demand for digital health solutions in the employer and health plan markets," stated Erez Raphael, Chief Executive Officer of Dario. "We generated sequential growth in revenue, improved gross margins and reduced operating expenses as our new business model matures. The strategic shift continues to yield results as we reduced our operating loss and net loss by 21.8% and 21.6% respectively, as compared to the first quarter of 2022, reflecting the higher profitability of the commercial channel.
"Business-to-Business (B2B) revenues continued to increase, representing approximately 70% of our total revenue during the first quarter, up from 56% in the first quarter of 2022. The increase in B2B share of total revenue reflects what we believe are growing trends in the market favoring Dario's single, integrated, multi-condition digital health platform.
"We were very pleased to complete a successful private placement offering of convertible preferred stock along with a concurrent refinancing of our credit facility which together adds significant runway which is expected to extend through late 2025. We believe that our strategy is working, and with our strengthened balance sheet and the significantly reduced cash burn, I believe Dario is well positioned to lead the market for integrated digital health solutions," Mr. Raphael concluded.
"Our partnership strategy continues with the addition of American Well Corporation (Amwell), a leading digital care delivery enablement platform, which will integrate our cardiometabolic solution into its offering," stated Rick Anderson, President of Dario. "Our agreement with Amwell represents a substantial opportunity for Dario with an installed base of approximately 2,000 health plans and hospitals that reach over 90 million lives. Amwell joins a growing list of strategic relationships that includes Sanofi US Services, Inc., CVS Pharmacy Inc., Virgin Pulse, Inc., Solera Health, Inc., and Alliant Insurance Services Inc., that we believe see the value of Dario for their health plan and employer clients. We believe that these relationships will enable us to continue to accelerate market penetration and drive revenue growth this year and beyond.
We are very excited about the first study conducted by Sanofi in one of the largest and most rigorous study designs seen in digital health with the use of the Dario solution. As the digital health industry matures partners, especially health plans, are demanding greater levels of evidence. This study demonstrated statistically significant reductions in health care utilization and a 23.5% reduction in hospitalizations. We believe that these results will be extremely valuable to our sales efforts for customers seeking to reduce cost in this increasingly challenging macro-economic environment.
We exited the first quarter with $67 million of signed contract value, a modest increase over the fourth quarter of 2022 as we have recently started the 2024 sales cycle for employers, and we have yet to reflect any contract value for Amwell. We continue to build a robust B2B business which we believe is strategically aligned with employer and health plan demand and anticipate that we will continue to see strong growth as a result of the foundation we have built," Mr. Anderson concluded.
Q1 2023 and Recent Highlights
First Quarter 2023 Results Summary
Revenues for the first quarter ended March 31, 2023 were $7.07 million, a 12.3% decrease from $8.06 million for the first quarter ended March 31, 2022, and an increase of 3.8% from $6.8 million for the fourth quarter of 2022. The decrease in revenues for the quarter ended March 31, 2023 as compared to the quarter ended March 31, 2022 resulted mainly from lower revenues from the Company's Business-to-Consumer (B2C) Channel.
Gross profit for the first quarter of 2023 was $3.2 million, a decrease of $0.8 million, compared to gross profit of $4 million for the first quarter of 2022, and an increase of 16% from $2.7 million for the fourth quarter of 2022. Gross profit as a percentage of revenues decreased to 44.8% in the first quarter of 2023, from 49.4% in the first quarter of 2022, and increased from 40.1% in the fourth quarter of 2022.
Pro-forma gross profit, excluding $1.1 million of amortization expenses related to the acquisition of technology, was $4.2 million, or 60.1% of revenues, for the three months ended March 31, 2023, compared to a pro-forma gross profit of $4.9 million, or 61% of revenues, for the three months ended March 31, 2022, and pro-forma-gross profit of $4 million, or 58.1% of revenues, for the three months ended December 31, 2022. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Total operating expenses for the first quarter of 2023 were $15.6 million, compared with $19.9 million for the first quarter of 2022, and $11.7 million for the fourth quarter of 2022, a decrease of $4.3 million, or 21.6%, compared to the first quarter of 2022, and an increase of $3.8 million, or 32.6%, compared to the fourth quarter of 2022. The decrease compared to the first quarter of 2022 resulted mainly from the decrease in our digital marketing expenses. The increase compared to the fourth quarter of 2022 resulted mainly from lower operating expenses in the fourth quarter of 2022 due to year-end adjustments in stock-based compensation expenses and headcount related items. Total operating expenses excluding stock-based compensation, acquisition expenses, earn-out measurement, and depreciation for the first quarter of 2023 were $10.6 million, compared to $14.8 million for the first quarter of 2022, and $10 million for the fourth quarter of 2022.
Operating loss for the first quarter of 2023 was $12.4 million, a decrease of $3.5 million, or 21.8%, compared to $15.9 million for the first quarter of 2022, and an increase of $3.4 million, or 37.7%, compared to $9.0 million for the fourth quarter of 2022. The decrease compared to the first quarter of 2022 and the increase compared to the fourth quarter of 2022, were mainly due to the decrease and increase respectively in our operating expenses.
Operating loss excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2023 were $6.3 million compared to $9.9 million for the first quarter of 2022, and $6.0 million for the fourth quarter of 2022.
Net loss was $12.8 million in the first quarter of 2023, a decrease of $3.1 million, or 19.4%, compared to a net loss of $15.9 million in the first quarter of 2022, and an increase of $0.2 million, or 1.7%, compared to $12.6 million for the fourth quarter of 2022. Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the first quarter of 2023 was $6.8 million compared to $9.9 million for the first quarter of 2022 and $9.6 million in the fourth quarter of 2022.
Non-GAAP billings for the three months ended March 31, 2023, were $6.7 million, a 16% decrease from $8.0 million for the three months ended March 31, 2022. The decrease is a result of lower sales generated in the B2C channel, in the three months ended March 31, 2023, compared to the three months ended March 31, 2022.
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details: Thursday, May 11, 8:30am ET
Dial-in: 1-833-816-1389 (domestic) or 1-412-317-0482 (international)
Call me™: https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNQ==
Passcode: 9873766
Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.
Conference title: DarioHealth Corp. – First Quarter 2023 Results Call
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1610598&tp_key=6f49dba576
Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through Sunday, June 11, 2023. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 10178111.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when it discusses that its increase in B2B share of total revenue reflects growing trends in the market favoring its single, integrated, multi-condition digital health platform, its expected runway, the belief that with its strengthened balance sheet and the significantly reduced cash burn, it is well positioned to lead the market for integrated digital health solutions, that its agreement with Amwell represents a substantial opportunity, that its growing list of strategic relationships reflects the value of its platform for health plan and employer clients, that such relationships will enable it to continue to accelerate market penetration and drive revenue growth this year and beyond, the expected timing of its product launches, that the study results will be valuable to its sales efforts for customers seeking to reduce cost and that its B2B is strategically aligned with employer and health plan demand and that it anticipate that it will continue to see strong growth. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expense provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory, depreciation of fixed assets, earn-out remeasurement and acquisition related expenses and amortization. We believe these measures provide useful information to management and investors for analysis of our operating results.
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | |||||||
INTERIM CONSOLIDATED BALANCE SHEETS | |||||||
U.S. dollars in thousands | |||||||
March 31, | December 31, | ||||||
2023 | 2022 | ||||||
Unaudited | |||||||
ASSETS | |||||||
CURRENT ASSETS: | |||||||
Cash and cash equivalents | $ | 38,789 | $ | 49,357 | |||
Short-term investments | 4,304 | - | |||||
Short-term restricted bank deposits | 225 | 165 | |||||
Trade receivables | 2,797 | 6,416 | |||||
Inventories | 6,877 | 7,956 | |||||
Other accounts receivable and prepaid expenses | 2,484 | 1,630 | |||||
Total current assets | 55,476 | 65,524 | |||||
NON-CURRENT ASSETS: | |||||||
Deposits | 6 | 6 | |||||
Operating lease right of use assets | 1,170 | 1,206 | |||||
Long-term assets | 149 | 111 | |||||
Property and equipment, net | 765 | 788 | |||||
Intangible assets, net | 8,803 | 9,916 | |||||
Goodwill | 41,640 | 41,640 | |||||
Total non-current assets | 52,533 | 53,667 | |||||
Total assets | $ | 108,009 | $ | 119,191 | |||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
INTERIM CONSOLIDATED BALANCE SHEETS | ||||||
U.S. dollars in thousands (except stock and stock data) | ||||||
March 31, | December 31, | |||||
2023 | 2022 | |||||
Unaudited | ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Trade payables | $ | 1,883 | $ | 2,322 | ||
Deferred revenues | 925 | 1,320 | ||||
Operating lease liabilities | 291 | 293 | ||||
Other accounts payable and accrued expenses | 5,935 | 6,592 | ||||
Loan, current | 8,583 | 8,823 | ||||
Total current liabilities | 17,617 | 19,350 | ||||
NON-CURRENT LIABILITIES | ||||||
Operating lease liabilities | 751 | 827 | ||||
Long-term loan | 16,745 | 18,105 | ||||
Warrant liability | 830 | 910 | ||||
Other long-term liabilities | 36 | — | ||||
Total non-current liabilities | 18,362 | 19,842 | ||||
STOCKHOLDERS' EQUITY | ||||||
Common stock of $0.0001 par value - Authorized: 160,000,000 shares; Issued and | 3 | 3 | ||||
Preferred stock of $0.0001 par value - Authorized: 5,000,000 shares; Issued and | *) - | *) - | ||||
Additional paid-in capital | 370,702 | 365,846 | ||||
Accumulated deficit | (298,675) | (285,850) | ||||
Total stockholders' equity | 72,030 | 79,999 | ||||
Total liabilities and stockholders' equity | $ | 108,009 | $ | 119,191 | ||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||||
U.S. dollars in thousands (except stock and stock data) | ||||||
Three months ended | ||||||
March 31, | ||||||
2023 | 2022 | |||||
Unaudited | ||||||
Revenues: | ||||||
Services | $ | 5,257 | $ | 4,984 | ||
Consumer hardware | 1,809 | 3,075 | ||||
Total revenues | 7,066 | 8,059 | ||||
Cost of revenues: | ||||||
Services | 1,477 | 452 | ||||
Consumer hardware | 1,340 | 2,689 | ||||
Amortization of acquired intangible assets | 1,081 | 932 | ||||
Total cost of revenues | 3,898 | 4,074 | ||||
Gross profit | 3,168 | 3,985 | ||||
Operating expenses: | ||||||
Research and development | $ | 5,165 | $ | 5,927 | ||
Sales and marketing | 6,340 | 9,535 | ||||
General and administrative | 4,071 | 4,395 | ||||
Total operating expenses | 15,576 | 19,857 | ||||
Operating loss | 12,408 | 15,872 | ||||
Total financial expenses, net | 417 | 44 | ||||
Net loss | $ | 12,825 | $ | 15,916 | ||
Other comprehensive loss: | ||||||
Deemed dividend | $ | - | $ | 451 | ||
Net loss attributable to shareholders | $ | 12,825 | $ | 16,367 | ||
Net loss per share: | ||||||
Basic and diluted loss per share of common stock | $ | 0.45 | $ | 0.74 | ||
Weighted average number of common stock used in computing basic and diluted net | 27,570,013 | 19,624,079 | ||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
U.S. dollars in thousands | ||||||
Three months ended | ||||||
March 31, | ||||||
2023 | 2022 | |||||
Unaudited | ||||||
Cash flows from operating activities: | ||||||
Net loss | $ | (12,825) | $ | (15,916) | ||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation, common stock, and payment in stock to directors, employees, | 4,856 | 5,343 | ||||
Depreciation | 97 | 70 | ||||
Change in operating lease right of use assets | 36 | 7 | ||||
Amortization of acquired intangible assets | 1,113 | 963 | ||||
Decrease (increase) in trade receivables | 3,619 | (3,264) | ||||
Increase in other accounts receivable, prepaid expense and long-term assets | (892) | (1,550) | ||||
Decrease (increase) in inventories | 1,079 | (1,555) | ||||
Decrease in trade payables | (439) | (890) | ||||
Decrease in other accounts payable and accrued expenses | (621) | (721) | ||||
Decrease in deferred revenues | (395) | (102) | ||||
Change in operating lease liabilities | (78) | (27) | ||||
Remeasurement of earn-out | - | (452) | ||||
Non-Cash financial income | (307) | - | ||||
Net cash used in operating activities | (4,757) | (18,094) | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment | (74) | (66) | ||||
Purchase of short-term investments | (4,996) | - | ||||
Proceeds from redemption of short-term investments | 708 | - | ||||
Cash paid as part of Upright Technologies Ltd. acquisition | - | (115) | ||||
Net cash used in investing activities | (4,362) | (181) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock and prefunded warrants (net of issuance costs) | - | 38,023 | ||||
Principal payments on long-term loan | (1,389) | - | ||||
Net cash provided by financing activities | (1,389) | 38,023 | ||||
Increase in cash, cash equivalents and restricted cash and cash equivalents | (10,508) | 19,748 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 49,470 | 35,948 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 38,962 | $ | 55,696 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest on long-term loan | $ | 1,072 | $ | - | ||
Non-cash activities: | ||||||
Right-of-use assets obtained in exchange for lease liabilities | $ | 28 | $ | 58 | ||
Reconciliation of Revenue to Billing (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Three Months Ended March 31, | ||||||||
2023 | 2022 | |||||||
GAAP Revenue | 7,066 | 8,059 | ||||||
Add: | ||||||||
Change in deferred revenue | (395) | (102) | ||||||
Billing (Non-GAAP) | 6,671 | 7,957 | ||||||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Three months ended March 31, 2023 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 3,898 | (27) | (1,112) | 2,759 | |||
Gross Profit | 3,168 | 27 | 1,112 | 4,307 | ||||
Research and development | 5,165 | (1,185) | (19) | 3,961 | ||||
Sales and Marketing | 6,340 | (1,847) | (44) | 4,449 | ||||
General and Administrative | 4,071 | (1,797) | (35) | 2,239 | ||||
Total Operating Expenses | 15,576 | (4,829) | (98) | 10,649 | ||||
Operating Loss | $ | (12,408) | 4,856 | 1,210 | (6,342) | |||
Financing expenses | 417 | - | - | 417 | ||||
Income Tax | - | - | ||||||
Net Loss | $ | (12,825) | 4,856 | 1,210 | (6,759) | |||
Three months ended March 31, 2022 | ||||||||
GAAP | Stock-Based | Earn-out | Non-GAAP | |||||
Cost of Revenues | $ | 4,074 | (23) | (954) | 3,097 | |||
Gross Profit | 3,985 | 23 | 954 | 4,962 | ||||
Research and development | 5,927 | (1,488) | (11) | 4,428 | ||||
Sales and Marketing | 9,535 | (1,651) | (41) | 7,843 | ||||
General and Administrative | 4,395 | (2,181) | 338 | 2,552 | ||||
Total Operating Expenses | 19,857 | (5,320) | 286 | 14,823 | ||||
Operating Loss | $ | (15,872) | 5,343 | 668 | (9,861) | |||
Financing income | 44 | - | 44 | |||||
Income Tax | - | |||||||
Net Loss | $ | (15,916) | 5,343 | 668 | (9,905) | |||
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-312-593-4280
Media Contact:
Scott Stachowiak
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-646-942-5630
| Last Trade: | US$0.87 |
| Daily Change: | 0.09 11.92 |
| Daily Volume: | 11,186 |
| Market Cap: | US$26.220M |
November 07, 2024 November 04, 2024 October 17, 2024 October 01, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
